• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Verily picks up former FDA commissioner Califf

Verily picks up former FDA commissioner Califf

May 17, 2017 By Fink Densford

Verily Logo

Former FDA commissioner Dr. Robert Califf said today that he will be joining Verily Life Sciences, the medical arm of Google parent Alphabet (NSDQ:GOOGL).

Califf said that in addition to his spot at Verily, he will also join Duke University, where he will work with the Duke Clinical Research Institute. Califf will also serve as an adjunct professor of medicine at Stanford University’s department of medicine, according to a Verily blog post.

“I’m excited to turn to a new career with Verily and Duke University. Although we are in the midst of an explosion of capability in the worlds of computing and information, we are still learning how to translate this capacity into better health and healthcare. Bridging this gap has been a recurring theme of my career, and it’s at the heart of what I hope to accomplish at both institutions. I’ll readily admit that I’ve chosen an ambitious problem to tackle, but I hope I can do my part,” Califf wrote in a Verily Blog post.

Califf did not say specifically what role he would take at the company, but indicated that he would use his experience at the head of the FDA to “offer insights that will allow the company to better tailor its technologies to meet the needs of doctors, other providers, health systems and the patients they serve, and to drive evidence-based approaches that will enable continuous learning and improvement,” according to the blog post.

“This work will not be easy. And while I’m excited about what Verily brings to this undertaking, widespread engagement with these issues across the entire biomedical ecosystem is needed as well. My hope is that Silicon Valley and entrepreneurs nationwide will collaborate on building an environment capable of linking the more than 300 million people in the U.S. to information that helps them live healthy, productive lives. Within this broad mission, I’m particularly focused on bridging a growing divide that has led to unprecedented health disparities as functions of income, education, race, and geography. But as increasingly ubiquitous smartphones and other electronic devices allow more and more people to access amazing sources of information and knowledge, we have the essential means to reverse these trends,” Califf wrote.

In April, Verily said it launched a 4-year, 10,000-patient study looking to examine how people transition from healthy to sick and to identify additional disease risk factors.

The company will partner with Duke University and Stanford Medicine, with enrollments beginning in the coming months. Study participants will also be enrolled at the California Health and Longevity Institute in Westlake Village, Calif.

The study will be the 1st initiative of its “Project Baseline,” which looks to establish a baseline definition for health and what it means.

Filed Under: Business/Financial News Tagged With: Alphabet (Google), Verily

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy